Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05709483 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Predictors of Aspirin Failure in Preeclampsia Prevention

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Nov 1, 2025 to Nov 1, 2026v7
  2. Primary and study completion dates: Nov 1, 2024 to Nov 1, 2025v6
  3. 2 versions Re-verified since Mar 30, 2023, no change to tracked fieldsv4-v5
  4. Start date: Mar 9, 2023 to Apr 13, 2023
    • Enrollment target: 120 to 130
    • Eligibility criteria expanded, about 70 words
    • Study arms: 1 to 2
    v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Feb 1, 2023 to Mar 9, 2023
    • Site details revised
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Hypertensive disorders of pregnancy (including preeclampsia) are among the leading causes of pregnancy complications and maternal deaths worldwide. They also increase the risks to the babies. Numerous interventions have been suggested in order to reduce the rate of preeclampsia. Low-dose aspirin is the most beneficial prophylactic approach in this regard. Nevertheless, aspirin failure is not uncommon. The genetic, laboratory, and clinical factors associated with low-dose aspirin failure in the prevention of preeclampsia are largely unknown. The presence of a genetic variant in PAR4 receptor expressed on platelets, is associated with increased platelet function and possibly with aspirin failure.
Trial Details
NCT Number NCT05709483
Lead Sponsor Rockefeller University
Conditions
(from sponsor)		 Preeclampsia
Related terms Pre-Eclampsia
Enrollment 130 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov